Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML

Inclusion Criteria:

1. Diagnosed with AML (the diagnostic criteria refer to WHO2022 standard, non-APL), andhave not received systemic anti-leukemia therapy (except hydroxyurea, low-dosecytarabine and other tumor reduction pretreatments);

2. Age ≥18 years old;

3. ECOG≤4;

4. The fertile woman agrees to use effective contraception during the treatment periodand up to 3 months after the end of the treatment; Sign the informed consent form.

Exclusion Criteria:

1. Known history of allergy to the investigational drug;

2. Resistance to azacytidine, azacitidine, Venetoclax;

3. Inability to take oral medication;

4. Combined with uncontrolled active infections (including bacterial, fungal or viralinfections);

5. Combined with uncontrolled major organ dysfunction: cardiac insufficiency,decompensated liver insufficiency, moderate/severe renal insufficiency, etc.;

6. Participating in other clinical studies that affect the main purpose of this study;Patients deemed unsuitable for participation in this study.